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Oral treatment of ichthyosis by
Summary Liarozole, a novel imidazole derivative, inhibits the cytochrome P45O-dependent 4-hydroxylation of
retinoic acid, resulting in increased tissue levels of retinoic acid. Twelve male patients with ichthyosis 
were given oral liarozole, 1.50 mg twice daily, in an open study for 12 weeks. Immunohistochemical 
parameters of inflammation, epidermal proliferation and differentiation were assessed before and 
after treatment. Extent and severity of the skin lesions was markedly reduced in all patients. Clinical 
side-effects were reminiscent of those with synthetic retinoids. No relevant changes were found in the 
haematological, urinary and biochemical parameters. Immunohistochemical assessment showed a 
statistically significant induction of keratin 4 after liarozole treatment in 10 of 12 patients. In two of 
these patients keratin 13 was induced. This open study showed that oral liarozole treatment was 
efficacious and well tolerated in the treatment of different types of ichthyosis. The immunohisto­
chemical results suggest a retinoid mechanism as the mode of action.
Retinoids (vitamin A-acid derivatives) are important 
compounds that control proliferation and differentia­
tion of epithelial tissues in mammals.1“4 Accordingly, 
systemic treatment with retinoids has yielded good 
results in the treatment of disorders of keratinization 
such as ichthyosis. However, their toxicity and terato­
genicity limit their use to severely affected patients.5”8 
Therefore, a search for new drugs with a broader toxic- 
therapeutic window is indicated.
Liarozole, a novel imidazole derivative, 
the cytochrome P450-dependent 4-hydroxylation of 
retinoic acid which is the physiological breakdown of 
all-irans-retinoic acid. In rats, liarozole increases 
the concentration of retinoic acid in plasma and
tissue.9 Liarozole several
P4 50-dependent steps in steroid biosynthesis, mainly 
the conversion of androgens to oestrogens (aromatase), 
progestins to androgens (17-hydroxylase, 17 -20-lyase) 
and of 11-deoxycorticosterone to corticosterone (11-
1 Mhydroxylase). Administration of 150 mg liarozole twice 
daily for 10 days to male volunteers showed neither 
reduction in cortisol levels, nor in the cortisol surge after 
adrenocorticotrophin hormone stimulation.11 Apart 
from a transient decrease of testosterone levels, no
Corret
changes of the levels of this hormone were observed. 
Furthermore, no abnormalities were observed in corti­
sol, cholesterol and one m
t r e e 1"
|  J
150 mg twice daily. One open trial 
7 5 -1 5 0  mg twice daily, in severe pk
75 to
liarozole,
showed a impi in 77% of the
Evidence is accumulating that liarozole will 
provide a broad efficacy side-effect window. However, 
final conclusions await further comparative studies.
The aim of the present study was to investigate the
tolerability of oral liarozole in 12
ichthyoses. Additionally, to 
vivo action of liarozole on 
disorders, immunohistochemical parameters of 
ini lamination, epidermal proliferation and differentia­
tion were assessed before and after treatment.
Patients and methods
In an open prospective study. I 
from various forms of ichthyosis were included: live
rk/'f\ I'O sis (XR1),
non- .Tinic U a r (NKLI), one
with erythrodermic lamellar ichthyosis (ELI) and two
bullous congenital ichthyosiform.
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(BCIE). They were treated with oral liarozole (liarozole 
lumarate), 1 5 0 mg twice daily, for 12 weeks. Topical as 
well as systemic treatments were stopped 2 and 4 
weeks before the start of the study, respectively. Patients 
were allowed to use bland emollients during the study 
except on the days of the visits. Only male patients aged 
18-70  years, were included. The patients with XRI had 
a documented steroid sulphatase deficiency, and sun 
exposure had to be avoided. Patients were examined 
before treatment, and at 0, 1, 2, 4, 8 and 12 weeks 
during the treatment phase, and 4 and 8 weeks after 
discontinuation of therapy. The severity of involvement 
was rated using a four-point scale for scaling, rough­
ness, erythema, bullae and hyperpigmentation, as
moderate; 3, severe. 
Scaling and roughness were recorded in all subgroups, 
erythema and bullae in ELI and BCIE, and hyperpig­
mentation only in XRI. The extent of involvement was 
expressed as the percentage of affected skin on arms, 
trunk and legs. An overall response to treatment was 
quantified by both the investigator and the patient,
-point scale: 0, deteriorated; 1, unchanged; 
2, moderately improved; 3, markedly improved; and 
4, cleared.
Haematological (haemoglobin, haematocrit, red 
blood count, white blood count and differential, platelet 
count), biochemical (Na, K, Cl, Ca, P, urea, creatinine, 
albumin, protein, total bilirubin, cholesterol, triglycer­
ides, alkaline phosphatase, transaminases and glucose)
follows: 0, absent; 1, mild; 2,
on a
and urinary gravity, pH, protein,
glucose, urobilinogen, bilirubin, red blood count and 
white blood count) were performed at entry, and at each 
visit alter start of treatment. Statistical analysis was 
carried out using the Wilcoxon signed-rank test for 
paired data.
In all 12 patients, punch biopsies were taken from 
representative skin lesions before and after treatment. 
The antibodies used to assess epidermal proliferation, 
keratinization, and epidermal and dermal inflam­
mation are summarized in Table 1. Immunohisto- 
chemical procedures were carried out as described 
previously.13
even
Results
Severity of skin involvement, assessed by the investi­
gator, is presented in Figure 1. For the extent of involve­
ment, a comparative curve was observed. As expected, 
the extent and severity of the ichthyosis deteriorated 
during the wash-out phase and, the 
during the first week of treatment. Thereafter, a clear 
clinical improvement for both the extent and severity of 
the skin lesions was achieved. At the end of the treat­
ment phase, an impressive clinical improvement was 
achieved in all patients (Figs 2 and 3 ). The extent of skin 
lesions was statistically significantly reduced for arms 
(P< 0-001), trunk (P =  0-002) and legs (P < 0-001). 
The degree of scaling and roughness, also significantly 
improved on the arms (P < 0-001), trunk (P =  0-001) 
and legs (P =  0-001). As hyperpigmentation, erythema 
and bullae were only assessed in a few patients (5,1 and 
2, respectively), no statistics were carried out. Never­
theless, changes in hyperpigmentation were compar­
able with changes in roughness and scaling. Erythema 
was not remarkably influenced. For overall response, 
both the investigator and 11 patients 
treatment as a marked improvement. One pi 
reported a moderate improvement. In six patients, 
after discontinuation of the treatment, the extent and 
severity of the lesions gradually worsened to reach
Table I . Specificity and sources of the antibodies
Antibody Specificity Source
Proliferation
Ki-6 7 Nuclear antigen Dakopatts, Copenhagen, Denmark
KcralinizUon
Ks8.12 Keratin 13 and 1f> Sigma, St Louis, U.S.A.
RKSE60 Keratin 10 Eurodiagnostics, Apeldoorn, the Netherlands
6B10 Keratin 4 Eurodiagnostics, Apeldoorn. the Netherlands
1C7 Keratin 13 Eurodiagnostics, Apeldoorn, the Netherlands
Inflammation
Anti-elastase Eiastase (polymorphonuclear leucocytes) Serotec, Oxford, U.K.
T il CD2 (T lymphocytes) Dakopatts, Copenhagen. Denmark
WT14 CD 14 (monocytes, macrophages) Department of Nephrology, Nijmegen, the Netherlands
OKT6 CD la  (Langerhans cells) Ortho Diagnostics Systems, Raritan, U.S.A.
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Table 2. Modulation of expression of keratins 4, 13 and 16, in the various ichthyosis subgroups, under influence of liarozole therapy
I
Parameter
X-linked recessive 
ichthyosis 
(n =  5)
Non-erythrodermic lamellar
ichthyosis
(n — 4)
Erythrodermic lamellar
ichthyosis
(n =  1)
Bullous congenital 
ichthyosiform erythroderma
(n =  2)
Keratin 4 (6B10)
unchanged 1 1 0 0
increased 4 3 1 2
Keratin 13 (1C7)
unchanged 5 4 0 1
increased 0 0 1 1
Keratin 13/16 (Ks8.12)
reduced 0 0 1 0
unchanged 1 3 0 1
increased 4 1 0 1
patients after 12 weeks of treatment, independently of 
the type of ichthyosis. The induction of keratin 4 was 
statistically significant ( P < 0 0 5 ) .  Keratin 13 could 
not be detected at baseline, but was sporadically 
detected in two patients after 12 weeks of treatment. 
The expression of keratins 13 and 16 was variable: 
increased in six patients, reduced in one and inconsis­
tent in five. Treatment with liarozole did not change the 
baseline expression of keratin 10 which could be 
detected within the suprabasal compartment. Before 
treatment, the average number of actively cycling cells 
(monoclonal antibody I<i-67) was 88-9 per mm of 
section. After 12 weeks of treatment, this number was 
86-6 (P < 0-10). None of the inflammatory parameters 
were significantly changed with treatment.
Discussion
Twelve patients with different types of ichthyosis, showed 
a statistically significant improvement in the extent and 
severity of the skin lesions after 12 weeks treatment 
with liarozole. As anticipated clinical side-effects were 
consistent with those experienced in hypervitaminosis A, 
i.e. mostly dry lips, dry eyes and itching. These effects 
were mild and did not necessitate discontinuation of the 
treatment. No significant changes were observed in the 
haematological, biochemical and urinary parameters. 
The present results suggest that liarozole provides a 
substantial clinical efficacy with limited side-effects.
The treatment of disorders of lceratinization has been 
revolutionized by systemic retinoids.14 However, the 
margin between safety and efficacy is limited for these 
drugs. Based on 12 patients, it is virtually impossible to 
conclude whether the therapeutic window between
efficacy and side-effects is broader for liarozole com­
pared with acitretin. However, the present study sug­
gests that liarozole is at least as effective, whereas the 
side-effect profile is rather similar to that of acitretin. In 
particular, the mucocutaneous side-effects that occur 
within the therapeutic dose range, is a characteristic for 
both treatments. Furthermore, dose-dependent blister­
ing occurs both during liarozole and acitretin treatment 
in BCIE.15 In our opinion, a double-blind comparative 
study between liarozole and acitretin is warranted in 
patients with ichthyosis. The development of a topical 
liarozole formulation could help to broaden the margin 
between efficacy and side-effects even more.
Although the clinical response in various disorders 
of keratinization, and mucocutaneous side-effects, 
suggest that liarozole might work via a retinoid effect, 
further evidence for such an effect might be provided by 
immunohistochemical studies on the cell biological 
effects during treatment. Immunohistochemical assess­
ment of biopsies revealed a statistically significant 
induction of the expression of keratin 4 in 10 of 12 
patients (P<0-Q5). In two patients, keratin 13 was 
induced. Keratins 4 and 13 are absent in normal 
adult human skin. Induction has been described after
treatment with topical retinoids. 16,17 Therefore, the
present results provide indirect evidence for the hypoth­
esis that the pharmacological effects of liarozole could 
be mediated by enhanced levels of endogenous retinoic 
acid. However, further studies on retinoid levels in the 
skin and induction of expression of cellular retinoic acid 
binding protein II are required before this hypothesis 
can be proven.
Theoretically, topical application of liarozole may be 
effective too. However, at the start of this study topical
1997 British Association of Dermatologists, British Journal ofDermatolom  136, 71-75
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liarozole was not available. Furthermore, topical reti­
noids used in the past were characterized by a high 
irritancy potential.18 Based on the good clinical results 
obtained with oral liarozole in this study, a topical 
liarozole formulation has been developed. Studies on 
topical liarozole in ichthyosis are ongoing.
In conclusion, in this open study, treatment with 
liarozole was followed by a substantial clinical improve­
ment in all patients with ichthyosis. Relevant laboratory 
side-effects were absent. Subjective side-effects were 
reminiscent of those observed with synthetic retinoids. 
The immunohistochemical results lend further support 
for a retinoid mechanism, although other modes of 
action are not excluded. Additional controlled studies 
are required to confirm the efficacy and to determine 
optimum dosage and safety profile of this new compound.
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